Hopso-LP
Generic Name
Ticagrelor
Manufacturer
Hypothetical Pharma Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| hopso lp 90 mg tablet | ৳ 1,000.00 | N/A |
Description
Overview of the medicine
Hopso-LP 90 mg tablet contains Ticagrelor, an antiplatelet medication used to prevent blood clots in patients with acute coronary syndrome (ACS) or a history of myocardial infarction.
Uses & Indications
Dosage
Adults
Acute Coronary Syndrome (ACS): Initiate with a single 180 mg loading dose (two 90 mg tablets), followed by 90 mg twice daily for the first year. After one year, consider 60 mg twice daily.
Elderly
No specific dose adjustment is required based on age.
Renal_impairment
No dose adjustment is necessary for patients with renal impairment.
How to Take
Take orally with or without food. Tablets can be crushed and mixed with water for patients who cannot swallow whole tablets.
Mechanism of Action
Ticagrelor is a P2Y12 platelet aggregation inhibitor. It selectively and reversibly binds to the P2Y12 receptor on the platelet surface, preventing ADP-mediated platelet activation and aggregation.
Pharmacokinetics
Onset
Within 30 minutes
Excretion
Predominantly biliary/fecal excretion (approx. 58%), with minor renal excretion (approx. 26%).
Half life
Approximately 7 hours for Ticagrelor and 9 hours for its active metabolite.
Absorption
Rapidly absorbed, peak plasma concentration (Cmax) achieved in approximately 1.5 hours for Ticagrelor and 2.5 hours for its active metabolite.
Metabolism
Primarily metabolized by CYP3A4, resulting in an active metabolite.
Side Effects
Contraindications
- Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage)
- History of intracranial hemorrhage
- Severe hepatic impairment
- Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin)
Drug Interactions
NSAIDs
Increased risk of bleeding; use with caution.
Aspirin
Typically co-administered, but high doses of aspirin (>100 mg daily) with Ticagrelor are not recommended for maintenance therapy.
Strong CYP3A4 Inducers (e.g., Rifampin, Phenytoin)
Decreased exposure to Ticagrelor; avoid co-administration.
Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Clarithromycin)
Increased exposure to Ticagrelor; avoid co-administration.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Overdose can lead to increased bleeding risk. Management involves supportive care and symptomatic treatment. Platelet transfusions are not expected to reverse the antiplatelet effect of Ticagrelor.
Pregnancy & Lactation
Pregnancy Category C. Use only if potential benefit justifies the potential risk to the fetus. It is unknown whether Ticagrelor is excreted in human milk; avoid use during lactation.
Side Effects
Contraindications
- Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage)
- History of intracranial hemorrhage
- Severe hepatic impairment
- Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin)
Drug Interactions
NSAIDs
Increased risk of bleeding; use with caution.
Aspirin
Typically co-administered, but high doses of aspirin (>100 mg daily) with Ticagrelor are not recommended for maintenance therapy.
Strong CYP3A4 Inducers (e.g., Rifampin, Phenytoin)
Decreased exposure to Ticagrelor; avoid co-administration.
Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Clarithromycin)
Increased exposure to Ticagrelor; avoid co-administration.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Overdose can lead to increased bleeding risk. Management involves supportive care and symptomatic treatment. Platelet transfusions are not expected to reverse the antiplatelet effect of Ticagrelor.
Pregnancy & Lactation
Pregnancy Category C. Use only if potential benefit justifies the potential risk to the fetus. It is unknown whether Ticagrelor is excreted in human milk; avoid use during lactation.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
36 months
Availability
Available in pharmacies nationwide
Approval Status
Approved by FDA and DGDA
Patent Status
Patent expired for generic versions, brand still holds some patents for specific formulations/indications.
WHO Essential Medicine
YesClinical Trials
Several large-scale clinical trials (e.g., PLATO, PEGASUS-TIMI 54) have demonstrated the efficacy and safety of Ticagrelor in preventing cardiovascular events.
Lab Monitoring
- Regular monitoring for signs of bleeding
- Hemoglobin and hematocrit levels
Doctor Notes
- Emphasize adherence to dual antiplatelet therapy (DAPT) duration as per guidelines.
- Carefully assess bleeding risk before initiating and during Ticagrelor therapy.
- Advise patients to inform all healthcare providers about Ticagrelor use before any surgery or dental procedure.
Patient Guidelines
- Take exactly as prescribed by your doctor.
- Do not stop taking this medicine without consulting your doctor, as it can increase your risk of heart attack or stroke.
- Report any signs of unusual bleeding or bruising immediately to your doctor.
Missed Dose Advice
If a dose is missed, take the next dose at its regularly scheduled time. Do not take a double dose to make up for a missed dose.
Driving Precautions
Ticagrelor is not expected to affect the ability to drive or operate machinery. However, if side effects like dizziness occur, caution is advised.
Lifestyle Advice
- Maintain a healthy diet and exercise regime.
- Avoid smoking and excessive alcohol consumption.
- Regularly monitor blood pressure and cholesterol levels.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.